AOD-9604 Peptide

Developed in the late 1990s/early 2000s as a focused hGH fragment, AOD-9604 was designed to isolate the lipolytic domain at the C-terminus of the somatotropin sequence from the regions of the parent hormone associated with growth-promoting receptor activity. Subsequent published summaries compiled program data on whether the fragment shared the IGF-1 pathway activity and immunogenicity characteristics of the full-length hormone.

Stier H. et al. (2013).

CAS #: 221231-10-3
Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular Weight: 1815.1 g/mol
PubChem ID: 71300630

AOD-9604 has been studied in signaling, structural, and systemic models, with research exploring its effects on lipid pathway dynamics, substrate utilization, and remodeling processes. Studies also highlight its potential influence on cartilage modeling, skeletal signaling, and pathway activity in preclinical settings.

Key Areas of Research:

• Signaling: Lipid pathways, substrate dynamics
• Structural: Cartilage, skeletal, connective matrix
• Systemic: Remodeling, viability, signaling

Together, these findings suggest experimental potential for AOD-9604 across signaling, structural, and systemic pathways. Because published work has compared the fragment with full-length hGH, including in β3-adrenergic receptor knockout mouse models, AOD-9604 provides a defined sequence for research into lipid-pathway signaling, receptor dependence, and structure-activity relationships within the somatotropin C-terminal region in laboratory settings.

Heffernan M. et al., 2001

Heffernan M. et al. (2001). Effects of hGH and its lipolytic fragment (AOD-9604) on lipid metabolism in obese and β3-AR knockout mice. Endocrinology 142(12):5182–5189.

Ng F.M. et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD-9604) of human growth hormone. Hormone Research 53(6):274–278. (Cited within FDA PCAC briefing).

Stier H., Vos E., Kenley D. (2013). Journal of Endocrinology & Metabolism.